# Beta Bionics, Inc.: financial statements, quarterly

BBNX · Nasdaq · CIK 1674632 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bbnx.md) · [Financials](/companies/bbnx/financials.md) · [Filings](/companies/bbnx/filings.md) · [Insiders](/companies/bbnx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bbnx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [12.9](/filings/0000950170-25-064504.md) | [15.0](/filings/0000950170-25-099652.md) | [16.7](/filings/0001193125-25-253538.md) | [20.4 d](/filings/0001193125-26-067065.md) | [17.6](/filings/0001193125-26-166843.md) | [23.2](/filings/0001193125-26-323777.md) | [27.3](/filings/0001674632-26-000003.md) | [32.1 d](/filings/0001193125-26-067065.md) | [27.6](/filings/0001193125-26-166843.md) | [32.0](/filings/0001193125-26-323777.md) | [35.5](/filings/0001674632-26-000003.md) |
| Cost of revenue | $m | [5.7](/filings/0000950170-25-064504.md) | [7.0](/filings/0000950170-25-099652.md) | [7.8](/filings/0001193125-25-253538.md) | [8.8 d](/filings/0001193125-26-067065.md) | [8.7](/filings/0001193125-26-166843.md) | [10.7](/filings/0001193125-26-323777.md) | [12.1](/filings/0001674632-26-000003.md) | [13.2 d](/filings/0001193125-26-067065.md) | [11.2](/filings/0001193125-26-166843.md) | [13.1](/filings/0001193125-26-323777.md) | [15.2](/filings/0001674632-26-000003.md) |
| Gross profit | $m | [7.2](/filings/0000950170-25-064504.md) | [8.1](/filings/0000950170-25-099652.md) | [8.9](/filings/0001193125-25-253538.md) | [11.7 d](/filings/0001193125-26-067065.md) | [9.0](/filings/0001193125-26-166843.md) | [12.5](/filings/0001193125-26-323777.md) | [15.1](/filings/0001674632-26-000003.md) | [18.9 d](/filings/0001193125-26-067065.md) | [16.4](/filings/0001193125-26-166843.md) | [18.9](/filings/0001193125-26-323777.md) | [20.3](/filings/0001674632-26-000003.md) |
| Research and development | $m | [5.5](/filings/0000950170-25-064504.md) | [6.4](/filings/0000950170-25-099652.md) | [5.1](/filings/0001193125-25-253538.md) | [9.2 d](/filings/0001193125-26-067065.md) | [7.6](/filings/0001193125-26-166843.md) | [8.9](/filings/0001193125-26-323777.md) | [8.2](/filings/0001674632-26-000003.md) | [10.1 d](/filings/0001193125-26-067065.md) | [10.4](/filings/0001193125-26-166843.md) | [10.2](/filings/0001193125-26-323777.md) | [12.0](/filings/0001674632-26-000003.md) |
| Operating income | $m | [(9.5)](/filings/0000950170-25-064504.md) | [(11.8)](/filings/0000950170-25-099652.md) | [(11.0)](/filings/0001193125-25-253538.md) | [(13.0) d](/filings/0001193125-26-067065.md) | [(18.6)](/filings/0001193125-26-166843.md) | [(19.9)](/filings/0001193125-26-323777.md) | [(17.0)](/filings/0001674632-26-000003.md) | [(16.1) d](/filings/0001193125-26-067065.md) | [(24.3)](/filings/0001193125-26-166843.md) | [(25.6)](/filings/0001193125-26-323777.md) | [(26.6)](/filings/0001674632-26-000003.md) |
| Net income | $m | [(12.4)](/filings/0000950170-25-064504.md) | [(14.5)](/filings/0000950170-25-099652.md) | [(9.7)](/filings/0001193125-25-253538.md) | [(18.1) d](/filings/0001193125-26-067065.md) | [(28.7)](/filings/0001193125-26-166843.md) | [(16.9)](/filings/0001193125-26-323777.md) | [(14.2)](/filings/0001674632-26-000003.md) | [(13.5) d](/filings/0001193125-26-067065.md) | [(21.9)](/filings/0001193125-26-166843.md) | [(23.4)](/filings/0001193125-26-323777.md) | [(24.4)](/filings/0001674632-26-000003.md) |
| Diluted EPS | $ per share | [(2.07)](/filings/0000950170-25-064504.md) | [(2.37)](/filings/0000950170-25-099652.md) | [(1.46)](/filings/0001193125-25-253538.md) | not reported | [(0.93)](/filings/0001193125-26-166843.md) | [(0.39)](/filings/0001193125-26-323777.md) | [(0.33)](/filings/0001674632-26-000003.md) | not reported | [(0.49)](/filings/0001193125-26-166843.md) | [(0.53)](/filings/0001193125-26-323777.md) | [(0.52)](/filings/0001674632-26-000003.md) |
| Basic EPS | $ per share | [(2.07)](/filings/0000950170-25-064504.md) | [(2.37)](/filings/0000950170-25-099652.md) | [(1.46)](/filings/0001193125-25-253538.md) | not reported | [(0.93)](/filings/0001193125-26-166843.md) | [(0.39)](/filings/0001193125-26-323777.md) | [(0.33)](/filings/0001674632-26-000003.md) | not reported | [(0.49)](/filings/0001193125-26-166843.md) | [(0.53)](/filings/0001193125-26-323777.md) | [(0.52)](/filings/0001674632-26-000003.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.6](/filings/0000950170-25-046762.md) | [22.1](/filings/0000950170-25-064504.md) | [13.0](/filings/0000950170-25-099652.md) | [17.5](/filings/0001193125-25-253538.md) | [30.4](/filings/0001193125-26-067065.md) | [42.5](/filings/0001193125-26-166843.md) | [35.1](/filings/0001193125-26-323777.md) | [38.5](/filings/0001674632-26-000003.md) | [31.6](/filings/0001674632-26-000003.md) | [30.2](/filings/0001193125-26-166843.md) | [44.3](/filings/0001193125-26-323777.md) | [81.6](/filings/0001674632-26-000003.md) |
| Current assets | $m | [104](/filings/0000950170-25-046762.md) | not reported | not reported | not reported | [133](/filings/0001193125-26-067065.md) | [262](/filings/0000950170-25-064504.md) | [286](/filings/0000950170-25-099652.md) | [270](/filings/0001193125-25-253538.md) | [268](/filings/0001674632-26-000003.md) | [248](/filings/0001193125-26-166843.md) | [231](/filings/0001193125-26-323777.md) | [293](/filings/0001674632-26-000003.md) |
| Total assets | $m | [110](/filings/0000950170-25-046762.md) | not reported | not reported | not reported | [150](/filings/0001193125-26-067065.md) | [338](/filings/0000950170-25-064504.md) | [330](/filings/0000950170-25-099652.md) | [330](/filings/0001193125-25-253538.md) | [329](/filings/0001674632-26-000003.md) | [304](/filings/0001193125-26-166843.md) | [292](/filings/0001193125-26-323777.md) | [444](/filings/0001674632-26-000003.md) |
| Current liabilities | $m | [10.6](/filings/0000950170-25-046762.md) | not reported | not reported | not reported | [21.1](/filings/0001193125-26-067065.md) | [16.5](/filings/0000950170-25-064504.md) | [19.5](/filings/0000950170-25-099652.md) | [25.4](/filings/0001193125-25-253538.md) | [30.9](/filings/0001674632-26-000003.md) | [23.2](/filings/0001193125-26-166843.md) | [26.0](/filings/0001193125-26-323777.md) | [32.8](/filings/0001674632-26-000003.md) |
| Total liabilities | $m | [51.4](/filings/0000950170-25-046762.md) | not reported | not reported | not reported | [73.6](/filings/0001193125-26-067065.md) | [24.3](/filings/0000950170-25-064504.md) | [28.3](/filings/0000950170-25-099652.md) | [35.3](/filings/0001193125-25-253538.md) | [41.1](/filings/0001674632-26-000003.md) | [33.2](/filings/0001193125-26-166843.md) | [36.0](/filings/0001193125-26-323777.md) | [42.4](/filings/0001674632-26-000003.md) |
| Shareholders' equity | $m | [(203)](/filings/0001193125-26-067065.md) | [(214)](/filings/0000950170-25-099652.md) | [(221)](/filings/0001193125-25-253538.md) | [(229)](/filings/0001193125-25-253538.md) | [(245)](/filings/0001674632-26-000003.md) | [314](/filings/0001193125-26-323777.md) | [302](/filings/0001674632-26-000003.md) | [295](/filings/0001674632-26-000003.md) | [288](/filings/0001674632-26-000003.md) | [271](/filings/0001193125-26-323777.md) | [256](/filings/0001674632-26-000003.md) | [401](/filings/0001674632-26-000003.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.1)](/filings/0000950170-25-064504.md) | [(12.2) d](/filings/0000950170-25-099652.md) | [(9.6) d](/filings/0001193125-25-253538.md) | [(14.3) d](/filings/0001193125-26-067065.md) | [(20.0)](/filings/0001193125-26-166843.md) | [(13.6) d](/filings/0001193125-26-323777.md) | [(8.7) d](/filings/0001674632-26-000003.md) | [(8.6) d](/filings/0001193125-26-067065.md) | [(23.8)](/filings/0001193125-26-166843.md) | [(14.6) d](/filings/0001193125-26-323777.md) | [(12.3) d](/filings/0001674632-26-000003.md) |
| Capital expenditure | $m | [0.4](/filings/0000950170-25-064504.md) | [0.5 d](/filings/0000950170-25-099652.md) | [1.9 d](/filings/0001193125-25-253538.md) | [0.6 d](/filings/0001193125-26-067065.md) | [0.3](/filings/0001193125-26-166843.md) | [1.8 d](/filings/0001193125-26-323777.md) | [1.3 d](/filings/0001674632-26-000003.md) | [1.9 d](/filings/0001193125-26-067065.md) | [1.4](/filings/0001193125-26-166843.md) | [1.0 d](/filings/0001193125-26-323777.md) | [2.3 d](/filings/0001674632-26-000003.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.0](/filings/0000950170-25-064504.md) | [6.1](/filings/0000950170-25-099652.md) | [6.7](/filings/0001193125-25-253538.md) | [30.7](/filings/0001193125-26-166843.md) | [43.4](/filings/0001193125-26-323777.md) | [43.6](/filings/0001674632-26-000003.md) | [44.4](/filings/0001193125-26-166843.md) | [44.5](/filings/0001193125-26-323777.md) | [46.5](/filings/0001674632-26-000003.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 54,367,067 at 2026-10-26, from the cover of the [10-Q filed 2026-10-27](/filings/0001674632-26-000003.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 27, 2026, 18:51 ET. No prices; not investment advice.